4.8 Article

Impaired sweating in patients with cholinergic urticaria is linked to low expression of acetylcholine receptor CHRM3 and acetylcholine esterase in sweat glands

期刊

FRONTIERS IN IMMUNOLOGY
卷 13, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.955161

关键词

acetylcholine esterase; cholinergic; urticaria; muscarinic 3 receptor; sweat gland; wheal; hypohidrosis; anhidrosis

资金

  1. Celldex
  2. Novartis
  3. Sanofi
  4. Moxie
  5. Allakos
  6. Amgen
  7. Aralez
  8. ArgenX
  9. AstraZeneca
  10. Centogene
  11. CSLBehring
  12. FAES
  13. Genentech
  14. GIInnovation
  15. Innate Pharma
  16. KyowaKirin
  17. Leo Pharma
  18. Lilly
  19. Menarini
  20. Roche
  21. Sanofi/Regeneron
  22. ThirdHarmonicBio
  23. UCB
  24. Uriach

向作者/读者索取更多资源

This study aimed to assess the rate and extent of impaired sweating in patients with cholinergic urticaria (CholU) and its association with disease duration and severity. The results showed that reduced sweating is common in CholU patients, especially in those with long-standing and severe disease. The reduced expression of CHRM3 and ACh-E may be responsible for the impaired sweating in these patients.
BackgroundCholinergic urticaria (CholU), a frequent form of chronic inducible urticaria, is characterized by itchy wheals and angioedema in response to sweating. As of now, the rate and pathophysiological relevance of impaired sweating in patients with CholU are ill-defined. AimTo assess in CholU patients the rate and extent of impaired sweating and its links to clinical and pathophysiological features of CholU. Patients and methodsWe assessed sweating in patients with CholU (n = 13) subjected to pulse-controlled ergometry (PCE) provocation testing. Pre- and post-PCE biopsies of lesional (L) and non-lesional (NL) skin were analyzed for the expression of acetylcholine receptor M3 (CHRM3) and acetylcholine esterase (ACh-E) by quantitative histomorphometry and compared to those of healthy control subjects (HCs). CholU patients were assessed for disease duration and severity as well as other clinical features. ResultsOf the 13 patients with CholU, 10 showed reduced sweating in response to PCE provocation, and 3 had severely reduced sweating. Reduced sweating was linked to long disease duration and high disease severity. CholU patients with impaired sweating responses showed reduced sweat gland epithelial expression of CHRM3 and ACh-E. ConclusionReduced sweating is common in CholU patients, especially in those with long-standing and severe disease, and it can be severe. Reduced expression of CHRM3 and ACh-E may be the cause or consequence of CholU in patients with impaired sweating, and this should be explored by further studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据